News
VANI
1.370
-1.44%
-0.020
Weekly Report: what happened at VANI last week (0803-0807)?
Weekly Report · 3d ago
Vivani Medical announces full enrollment, initial dosing in SLIM-1 trial
TipRanks · 6d ago
Vivani Completes Enrollment in SLIM-1 Semaglutide Implant Trial
TipRanks · 08/06 12:54
Weekly Report: what happened at VANI last week (0727-0731)?
Weekly Report · 08/03 09:04
Weekly Report: what happened at VANI last week (0720-0724)?
Weekly Report · 07/27 09:04
Weekly Report: what happened at VANI last week (0713-0717)?
Weekly Report · 07/20 09:04
Vivani Medical Highlights Upcoming SLIM-1 First Dosing Milestone
TipRanks · 07/17 09:32
Weekly Report: what happened at VANI last week (0706-0710)?
Weekly Report · 07/13 09:04
Weekly Buzz: JNJ, VERA Get FDA Nod; VRTX Snaps Up CRNX; MSLE Aces DMD Trial; IONS Misses Key Goal
NASDAQ · 07/10 16:10
Vivani Medical: Buy Rating Reaffirmed as Novo Nordisk Evaluation and Cortigent–ClearOne Merger Support $3.50 Price Target
TipRanks · 07/09 16:25
Vivani Medical In Deal With Novo Nordisk To Evaluate Semaglutide Drug Implant NPM-139
NASDAQ · 07/07 13:16
Vivani Medical (VANI) Receives a Buy from Lake Street
TipRanks · 07/07 12:56
Vivani in pact with Novo to study Wegovy implant
Seeking Alpha · 07/07 12:36
Vivani Advances GLP-1 Implant Program With Novo Nordisk
TipRanks · 07/07 12:18
Vivani Medical enters pact with Novo Nordisk to evaluate NPM-139
TipRanks · 07/07 11:46
Vivani Medical To Allow Novo Nordisk To Evaluate NPM-139, The Company’s Semaglutide Drug Implant
Benzinga · 07/07 11:36
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
Barchart · 07/07 06:35
Weekly Report: what happened at VANI last week (0629-0703)?
Weekly Report · 07/06 09:04
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 07/03 16:20
ClearOne signs merger deal to acquire Cortigent, plans $10M-$15M capital raise
Seeking Alpha · 07/02 13:28
More
Webull provides a variety of real-time VANI stock news. You can receive the latest news about Vivani Medical through multiple platforms. This information may help you make smarter investment decisions.
About VANI
Vivani Medical, Inc. is a clinical-stage biopharmaceutical company, developing miniature, ultra-long-acting drug implants. Leveraging its NanoPortal platform, it develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and to improve patient tolerance to their medication. Its lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in overweight individuals. Its pipeline includes NPM-139 (semaglutide implant), which is also under development for chronic weight management. NPM-119 refers to its six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables.